Shenlingcao oral liquid for patients with non-small cell lung cancer receiving adjuvant chemotherapy after radical resection: A multicenter randomized controlled trial

医学 化疗 内科学 随机对照试验 置信区间 肺癌 生活质量(医疗保健) 肿瘤科 辅助化疗 外科 癌症 护理部 乳腺癌
作者
Yanmei Liu,Xiaochao Luo,Jiali Liu,Yu Ma,Jing Tan,Wen Wang,Jian Hu,Xiangning Fu,Lin Xu,Fenglei Yu,Shidong Xu,Haitao Ma,Xiuyi Yu,Qingjun You,Zhi‐Qiang Wang,Ling Li,Xun Zhang,Xin Sun
出处
期刊:Phytomedicine [Elsevier BV]
卷期号:113: 154723-154723 被引量:22
标识
DOI:10.1016/j.phymed.2023.154723
摘要

Low quality of life (QoL) in patients with non-small cell lung cancer (NSCLC) receiving adjuvant chemotherapy after radical resection is a major global health issue. High-quality evidence for the effectiveness of Shenlingcao oral liquid (SOL) as a complementary treatment in this patients is lacking at present.To determine whether complementary SOL treatment in NSCLC patients receiving adjuvant chemotherapy would yield greater improvements in QoL than chemotherapy alone.We conducted a multicenter, randomized controlled trial of stages IIA-IIIA NSCLC patients undergoing adjuvant chemotherapy in seven hospitals.Using stratified blocks, participants were randomized in a 1:1 ratio to receive SOL combined with conventional chemotherapy or conventional chemotherapy alone. The primary outcome was the change in global QoL from baseline to the fourth chemotherapy cycle, and intention-to-treat analysis was applied with a mixed-effect model. Secondary outcomes were functional QoL, symptoms, and performance status scores at the 6-month follow-up. Missing data were handled with multiple imputation and a pattern-mixture model.Among 516 randomized patients, 446 (86.43%) completed the study. After the fourth chemotherapy cycle, in comparison with the control group, patients receiving SOL showed a lower reduction in mean global QoL (-2.76 vs. -14.11; mean difference [MD], 11.34; 95% confidence interval [CI], 8.28 to 14.41), greater improvement in physical function (MD, 11.61; 95% CI, 8.57 to 14.65), role function (MD, 10.15; 95% CI, 5.75 to 14.54), and emotional function (MD, 4.71; 95% CI, 1.85 to 7.57), and greater improvements in lung cancer-related symptoms (e.g., fatigue, nausea/vomiting, and appetite loss) and performance status during the 6-month follow-up period (treatment main effect, p < 0.05).SOL treatment for NSCLC patients receiving adjuvant chemotherapy can significantly improve QoL and performance status within 6 months after radical resection.ClinicalTrials.gov identifier: NCT03712969.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
夜枭完成签到,获得积分10
2秒前
酷波er的应助被马儿采纳,获得10
3秒前
生动的绮南完成签到,获得积分10
3秒前
3秒前
fox199753206完成签到,获得积分10
3秒前
5秒前
369ninja发布了新的文献求助10
6秒前
6秒前
Louis发布了新的文献求助10
6秒前
7秒前
7秒前
幽默的盼山完成签到,获得积分10
8秒前
传奇3的应助被徐枘采纳,获得10
8秒前
牛黄完成签到 ,获得积分10
8秒前
9秒前
9秒前
9秒前
10秒前
栗子完成签到,获得积分10
10秒前
10秒前
drizzle发布了新的文献求助10
10秒前
哈哈完成签到,获得积分20
10秒前
叮叮当当发布了新的文献求助10
11秒前
11秒前
JamesPei的应助被学习采纳,获得10
11秒前
11秒前
zhaoben发布了新的文献求助10
11秒前
阿皮的应助被dxxxxx采纳,获得30
11秒前
12秒前
hc发布了新的文献求助10
13秒前
yjt发布了新的文献求助10
14秒前
WZJ完成签到,获得积分20
14秒前
14秒前
15秒前
15秒前
15秒前
15秒前
热情曲奇发布了新的文献求助30
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184267
求助须知:如何正确求助?哪些是违规求助? 9573323
关于积分的说明 21830790
捐赠科研通 7781314
什么是DOI,文献DOI怎么找? 3434307
关于科研通互助平台的介绍 2558389
邀请新用户注册赠送积分活动 2480817